Circulating Galectin-3 in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction Treated with Mild Hypothermia: A Biomarker Sub-Study of the SHOCK-COOL Trial

Cheng, Wenke; Fuernau, Georg; Desch, Steffen; Freund, Anne; Feistritzer, Hans‐Josef; Pöss, Janine; Besler, Christian; Lurz, Philipp; Büttner, Petra; Thiele, Holger

doi:10.3390/jcm11237168

Cited by 6 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with lower serum Gal-3 concentration on the first day after admission demonstrated a higher risk of all-cause mortality at 30 days. Serum Gal-3 concentration on day 1 had a good predictive value for 30-day all-cause mortality with an area under the receiver operating characteristic curve of 0.696 (95% CI: 0.513−0.879), with an optimal cutoff point of less than 3.65 ng/mL [75].…”

Section: Predictor Of Prognosismentioning

confidence: 97%

The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?

Zaborska,

Sikora-Frąc,

Smarż

et al. 2023

IJMS

View full text Add to dashboard Cite

Heart failure (HF) is a clinical syndrome with high morbidity and mortality, and its prevalence is rapidly increasing. Galectin-3 (Gal-3) is an important factor in the pathophysiology of HF, mainly due to its role in cardiac fibrosis, inflammation, and ventricular remodeling. Fibrosis is a hallmark of cardiac remodeling, HF, and atrial fibrillation development. This review aims to explore the involvement of Gal-3 in HF and its role in the pathogenesis and clinical diagnostic and prognostic significance. We report data on Gal-3 structure and molecular mechanisms of biological function crucial for HF development. Over the last decade, numerous studies have shown an association between echocardiographic and CMR biomarkers in HF and Gal-3 serum concentration. We discuss facts and concerns about Gal-3’s utility in acute and chronic HF with preserved and reduced ejection fraction for diagnosis, prognosis, and risk stratification. Finally, we present attempts to use Gal-3 as a therapeutic target in HF.

show abstract

Section: Predictor Of Prognosismentioning

confidence: 97%

The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?

Zaborska,

Sikora-Frąc,

Smarż

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Особого внимания заслуживает выявленная нами статистически значимая положительная корреляционная связь содержания галектина-3 в плазме крови с возрастом в группе контроля (r s = 0,51, p < 0,05). Основываясь на данных отечественной и зарубежной литературы, можно предположить следующее: эта взаимосвязь обусловлена тем, что галектин-3 рассматривают как профибротическую молекулу, потенциальный маркер фиброза миокарда и печени [7,11,21], а с возрастом многократно возрастает риск развития хронической сердечной недостаточности и сердечно-сосудистых заболеваний. Тем не менее в группе больных РЖ корреляционной взаимосвязи исследуемых маркеров с возрастом мы не обнаружили.…”

Section: участие авторовunclassified

Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients

Короткова¹,

Samoilova³

et al. 2023

Almanac of Clinical Medicine

View full text Add to dashboard Cite

Background: High incidence of gastric cancer (GC), its aggressive clinical course, rapid tumor dissemination, low sensitivity to chemotherapy and lack of reliable laboratory diagnostic criteria urgently require a search for the most informative markers associated with key biologic properties of the tumors. Aim: Comparative analysis of galectin-3, matrix metalloproteinase (MMP)-2, and MMP-9 levels in peripheral blood of GC patients and healthy donors, assessment of association of these markers with clinical morphological characteristics of the disease, and prognosis of overall and relapse-free survival. Materials and methods: Sixty (60) primary treatment-nave GC patients (38 men, 22 women) aged 29 to 81 years and 90 healthy donors compatible with their age and sex were included into the study. Galectin-3 was measured in EDTA plasma, MMP-2 and MMP-9 in serum with standard direct enzyme immunoassay kits "Human MMP-2 (total)", "Human MMP-9 (total)", "Human Galectin-3" (RD Systems, USA). Results: Plasma galectin-3 concentration in the GC patients was significantly higher than in the healthy controls (median 12.9 and 10.6 ng/ml, respectively; p 0.0001). No difference in serum MMP-9 levels between GC patients and control subjects were found, while MMP-2 level in the control group was significantly higher, than in the GC patients (p = 0.039). No association between galectin-3, MMP-2, and MMP-9 blood levels in the GC patients could be identified. In contrast to GC patients, there was a positive correlation of plasma galectin-3 with age in the control group (rs = 0.51, p 0.005). No associations between the biomarkers levels in blood and clinical and morphological characteristics of GC were established, except MMP-9 being higher at Т4а invasion depth as compared to the earlier Т2 level. Marked differences in the overall survival depending on plasma galectin-3 levels were found, with the cut-off level of 12.9 ng/ml: the 5-year overall survival in the patients with low galectin-3 was better, than in those with its higher level (50 and 43%, respectively; however, the difference was non-significant, р 0.1). Both overall and relapse-free survival of the GC patients was higher in those with low ( 212 ng/ml) serum MMP-2: the 5-year overall survival in this group comprised 60% versus 23% in the patients with higher MMP-2 (p = 0.018). The difference in relapse-free survival was non-significant. Serum MMP-9 levels had no significant impact on the survival of GC patients. Conclusion: The ambiguous data on the clinical role of galectin-3, MMP-2, MMP-9 in GC obtained in this study indicate the necessity of further investigation of their possible utility for the diagnostics and prognosis of treatment results.

show abstract

“…In a similar fashion, a review performed on pediatric studies that enrolled patients diagnosed with heart failure concluded that none of the currently available serum biomarkers of myocardial fibrosis perform as well as NT-proBNP in predicting ventricular dysfunction [ 64 ]. Gal-3 was afterwards regarded by the randomized SHOCK-COOL trial as a stable biomarker that correlates well with a 30-day mortality of different causes in patients with AHF and which is not influenced by age, sex and body mass index [ 65 ]. It is therefore unsurprising that Gal-3 has been proposed as a diagnostic biomarker and potential therapeutic target in AHF [ 66 ].…”

Section: Gal-3 Heart Failure and Its Associated Complicationsmentioning

confidence: 99%

The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature

Făgărășan

Săsăran

Gozar

et al. 2023

IJMS

View full text Add to dashboard Cite

Galectin-3 (Gal-3) is a novel pro-fibrotic biomarker that can predict both right and left cardiac dysfunction caused by various cardiovascular conditions. Its expression seems to be progressively altered with evolving cardiac remodeling processes, even before the onset of heart failure. Hence, Gal-3 has been found to be an individual predictor of acute and chronic heart failure or to serve as part of an integrated biomarker panel that can foresee adverse cardiac outcomes. In congenital heart disease (CHD), Gal-3 correlates with cardiac mortality and complications in both children and adults and is proposed as a therapeutic target in order to reverse the activation of pro-fibrosis pathways that lead to heart failure. Positive associations between serum Gal-3 levels, post-operatory hospitalization rates, complications and ventricular dysfunction have also been reported within studies conducted on patients with CHD who underwent corrective surgery. Thus, this review tried to address the potential utility of Gal-3 in patients with CHD and particularly in those who undergo corrective surgery. The heterogeneity of the literature data and the lack of validation of the results obtained by the current studies on larger cohorts cannot be neglected, though. Further longitudinal research is required to establish how Gal-3 can relate to long-term outcomes in pediatric CHD.

show abstract

Circulating Galectin-3 in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction Treated with Mild Hypothermia: A Biomarker Sub-Study of the SHOCK-COOL Trial

Cited by 6 publications

References 48 publications

The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?

The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?

Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients

The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature

Contact Info

Product

Resources

About